Harmony Biosciences Holdings, Inc. (HRMY)

$52

+3.23 (+6.62%)
Rating:
Recommendation:
-
Symbol HRMY
Price $52
Beta 0.000
Volume Avg. 0.52M
Market Cap 3.071B
Shares () -
52 Week Range 25.09-54.0
1y Target Est -
DCF Unlevered HRMY DCF ->
DCF Levered HRMY LDCF ->
ROE 28.66% Buy
ROA 10.49% Buy
Operating Margin -
Debt / Equity 116.32% Buy
P/E 65 Strong Buy
P/B 14.28 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HRMY news


Mr. John Charles Jacobs M.B.A.
Healthcare
Biotechnology
NASDAQ Global Market

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.